TP53 and cleidocranial dysplasia 1: Altogether, these data suggest that heterozygous RUNX2 mutations in both CCD patients impair osteogenic maturation by reducing the expression of RUNX2-downstream genes, such as SPARC, as well as by reducing p53 levels (Figure 8).